Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The preliminary performance of the system in real-world settings was evaluated. Data uploaded from August 2020 to March 2021 by individuals livi...
Uloženo v:
| Vydáno v: | Diabetes technology & therapeutics Ročník 24; číslo 2; s. 113 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.02.2022
|
| Témata: | |
| ISSN: | 1557-8593, 1557-8593 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The preliminary performance of the system in real-world settings was evaluated.
Data uploaded from August 2020 to March 2021 by individuals living in Belgium, Finland, Italy, the Netherlands, Qatar, South Africa, Sweden, Switzerland, and the United Kingdom were aggregated and retrospectively analyzed to determine the mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR), and above (TAR) glycemic ranges, system use, and insulin consumption in users having ≥10 days of sensor glucose (SG) data after initiating AHCL. The impact of initiating AHCL was evaluated in a subgroup of users also having ≥10 days of SG data, before AHCL initiation.
Users (
= 4120) were observed for a mean of 54 ± 32 days. During this time, they spent a mean of 94.1% ± 11.4% of the time in AHCL and achieved a mean GMI of 6.8% ± 0.3%, TIR of 76.2% ± 9.1%, TBR <70 of 2.5% ± 2.1%, and TAR >180 of 21.3% ± 9.4%, after initiating AHCL. There were 77.3% and 79.0% of users who achieved a TIR >70% and a GMI of <7.0%, respectively. Users for whom comparison with pre-AHCL was possible (
= 812) reduced their GMI by 0.4% ± 0.4% (
= 0.005) and increased their TIR by 12.1% ± 10.5% (
< 0.0001), post-AHCL initiation. More users achieved the glycemic treatment goals of GMI <7.0% (37.6% vs. 75.2%,
< 0.0001) and TIR >70% (34.6% vs. 74.9%,
< 0.0001) when compared with pre-AHCL initiation.
Most MiniMed 780G system users achieved TIR >70% and GMI <7%, while minimizing hypoglycemia, in a real-world condition. |
|---|---|
| AbstractList | Background: The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The preliminary performance of the system in real-world settings was evaluated. Methods: Data uploaded from August 2020 to March 2021 by individuals living in Belgium, Finland, Italy, the Netherlands, Qatar, South Africa, Sweden, Switzerland, and the United Kingdom were aggregated and retrospectively analyzed to determine the mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR), and above (TAR) glycemic ranges, system use, and insulin consumption in users having ≥10 days of sensor glucose (SG) data after initiating AHCL. The impact of initiating AHCL was evaluated in a subgroup of users also having ≥10 days of SG data, before AHCL initiation. Results: Users (N = 4120) were observed for a mean of 54 ± 32 days. During this time, they spent a mean of 94.1% ± 11.4% of the time in AHCL and achieved a mean GMI of 6.8% ± 0.3%, TIR of 76.2% ± 9.1%, TBR <70 of 2.5% ± 2.1%, and TAR >180 of 21.3% ± 9.4%, after initiating AHCL. There were 77.3% and 79.0% of users who achieved a TIR >70% and a GMI of <7.0%, respectively. Users for whom comparison with pre-AHCL was possible (N = 812) reduced their GMI by 0.4% ± 0.4% (P = 0.005) and increased their TIR by 12.1% ± 10.5% (P < 0.0001), post-AHCL initiation. More users achieved the glycemic treatment goals of GMI <7.0% (37.6% vs. 75.2%, P < 0.0001) and TIR >70% (34.6% vs. 74.9%, P < 0.0001) when compared with pre-AHCL initiation. Conclusion: Most MiniMed 780G system users achieved TIR >70% and GMI <7%, while minimizing hypoglycemia, in a real-world condition.Background: The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The preliminary performance of the system in real-world settings was evaluated. Methods: Data uploaded from August 2020 to March 2021 by individuals living in Belgium, Finland, Italy, the Netherlands, Qatar, South Africa, Sweden, Switzerland, and the United Kingdom were aggregated and retrospectively analyzed to determine the mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR), and above (TAR) glycemic ranges, system use, and insulin consumption in users having ≥10 days of sensor glucose (SG) data after initiating AHCL. The impact of initiating AHCL was evaluated in a subgroup of users also having ≥10 days of SG data, before AHCL initiation. Results: Users (N = 4120) were observed for a mean of 54 ± 32 days. During this time, they spent a mean of 94.1% ± 11.4% of the time in AHCL and achieved a mean GMI of 6.8% ± 0.3%, TIR of 76.2% ± 9.1%, TBR <70 of 2.5% ± 2.1%, and TAR >180 of 21.3% ± 9.4%, after initiating AHCL. There were 77.3% and 79.0% of users who achieved a TIR >70% and a GMI of <7.0%, respectively. Users for whom comparison with pre-AHCL was possible (N = 812) reduced their GMI by 0.4% ± 0.4% (P = 0.005) and increased their TIR by 12.1% ± 10.5% (P < 0.0001), post-AHCL initiation. More users achieved the glycemic treatment goals of GMI <7.0% (37.6% vs. 75.2%, P < 0.0001) and TIR >70% (34.6% vs. 74.9%, P < 0.0001) when compared with pre-AHCL initiation. Conclusion: Most MiniMed 780G system users achieved TIR >70% and GMI <7%, while minimizing hypoglycemia, in a real-world condition. The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The preliminary performance of the system in real-world settings was evaluated. Data uploaded from August 2020 to March 2021 by individuals living in Belgium, Finland, Italy, the Netherlands, Qatar, South Africa, Sweden, Switzerland, and the United Kingdom were aggregated and retrospectively analyzed to determine the mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR), and above (TAR) glycemic ranges, system use, and insulin consumption in users having ≥10 days of sensor glucose (SG) data after initiating AHCL. The impact of initiating AHCL was evaluated in a subgroup of users also having ≥10 days of SG data, before AHCL initiation. Users ( = 4120) were observed for a mean of 54 ± 32 days. During this time, they spent a mean of 94.1% ± 11.4% of the time in AHCL and achieved a mean GMI of 6.8% ± 0.3%, TIR of 76.2% ± 9.1%, TBR <70 of 2.5% ± 2.1%, and TAR >180 of 21.3% ± 9.4%, after initiating AHCL. There were 77.3% and 79.0% of users who achieved a TIR >70% and a GMI of <7.0%, respectively. Users for whom comparison with pre-AHCL was possible ( = 812) reduced their GMI by 0.4% ± 0.4% ( = 0.005) and increased their TIR by 12.1% ± 10.5% ( < 0.0001), post-AHCL initiation. More users achieved the glycemic treatment goals of GMI <7.0% (37.6% vs. 75.2%, < 0.0001) and TIR >70% (34.6% vs. 74.9%, < 0.0001) when compared with pre-AHCL initiation. Most MiniMed 780G system users achieved TIR >70% and GMI <7%, while minimizing hypoglycemia, in a real-world condition. |
| Author | Cohen, Ohad Battelino, Tadej Arrieta, Arcelia Lepore, Giuseppe Shin, John Silva, Julien Da Castañeda, Javier Grossman, Benyamin |
| Author_xml | – sequence: 1 givenname: Julien Da surname: Silva fullname: Silva, Julien Da organization: Medtronic International Trading Sàrl, Tolochenaz, Switzerland – sequence: 2 givenname: Giuseppe surname: Lepore fullname: Lepore, Giuseppe organization: Unit of Endocrine Diseases and Diabetology, ASST Papa Giovanni XXIII, Bergamo, Italy – sequence: 3 givenname: Tadej orcidid: 0000-0002-0273-4732 surname: Battelino fullname: Battelino, Tadej organization: University Children's Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia – sequence: 4 givenname: Arcelia surname: Arrieta fullname: Arrieta, Arcelia organization: Medtronic Bakken Research Center, Maastricht, The Netherlands – sequence: 5 givenname: Javier surname: Castañeda fullname: Castañeda, Javier organization: Medtronic Bakken Research Center, Maastricht, The Netherlands – sequence: 6 givenname: Benyamin surname: Grossman fullname: Grossman, Benyamin organization: Medtronic, Northridge, California, USA – sequence: 7 givenname: John surname: Shin fullname: Shin, John organization: Medtronic, Northridge, California, USA – sequence: 8 givenname: Ohad orcidid: 0000-0003-4337-1795 surname: Cohen fullname: Cohen, Ohad organization: Medtronic International Trading Sàrl, Tolochenaz, Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34524003$$D View this record in MEDLINE/PubMed |
| BookMark | eNpN0L1OwzAUBWALFdEfGFmRR5aUazt2YjZU0YJEVVSo2Iic-EYEJXGxk6E7T8Kj8SSAKBLTOcOnM5wxGbSuRUJOGUwZpPrCVmbKgbMpcBAHZMSkTKJUajH414dkHMIrACSCsyMyFLHkMYAYkec1mjp6cr629B596Xxj2gKpK2n3gnRZtdUS7ef7B01SWNCHXeiwuaTzyoeOrnHrfPdjV31XuAYDLb1raMw40E1AH47JYWnqgCf7nJDN_PpxdhPdrRa3s6u7qJBMdZHRVhnFYy2VlKBSq1OrLLO5ToxVOUebCwaSJUXCjJYgwOhSSB0LFDblBZ-Q89_drXdvPYYua6pQYF2bFl0fMi4TruNYcPVNz_a0zxu02dZXjfG77O8T_gWbSGMd |
| CitedBy_id | crossref_primary_10_1177_19322968231153882 crossref_primary_10_1111_1753_0407_13426 crossref_primary_10_1111_dme_15078 crossref_primary_10_1007_s13300_022_01252_w crossref_primary_10_1177_19322968231182406 crossref_primary_10_2337_dc22_1692 crossref_primary_10_1186_s13098_023_01184_w crossref_primary_10_1089_dia_2023_0348 crossref_primary_10_1111_pedi_13440 crossref_primary_10_1111_dom_14713 crossref_primary_10_1016_j_diabres_2024_111832 crossref_primary_10_1089_dia_2023_0467 crossref_primary_10_1177_15209156251376708 crossref_primary_10_1089_dia_2023_0589 crossref_primary_10_1007_s00592_024_02315_z crossref_primary_10_1210_endrev_bnac022 crossref_primary_10_1111_dom_15008 crossref_primary_10_1016_j_bbrc_2025_152415 crossref_primary_10_1016_j_numecd_2022_03_031 crossref_primary_10_1016_j_diabres_2023_110907 crossref_primary_10_1089_dia_2024_0073 crossref_primary_10_3389_fendo_2025_1670266 crossref_primary_10_1055_a_1911_2926 crossref_primary_10_1089_dia_2023_0112 crossref_primary_10_3390_life13030783 crossref_primary_10_3390_nu15234875 crossref_primary_10_1063_5_0152290 crossref_primary_10_1007_s12020_024_03881_6 crossref_primary_10_1016_j_diabres_2022_110052 crossref_primary_10_3233_THC_230490 crossref_primary_10_3389_fendo_2025_1590964 crossref_primary_10_3390_bios15080543 crossref_primary_10_2337_dc23_1355 crossref_primary_10_1111_dom_16103 crossref_primary_10_1111_dom_15139 crossref_primary_10_1089_dia_2025_0134 crossref_primary_10_1016_j_jcjd_2022_09_117 crossref_primary_10_1111_dom_16226 crossref_primary_10_2337_dc22_1217 crossref_primary_10_3390_children11070839 crossref_primary_10_1007_s00125_024_06218_0 crossref_primary_10_1177_19322968231161320 crossref_primary_10_3390_jcm12216951 crossref_primary_10_1111_1753_0407_13490 crossref_primary_10_3389_fdgth_2025_1596188 crossref_primary_10_1177_19322968231187915 crossref_primary_10_1089_dia_2023_0123 crossref_primary_10_1111_dme_15333 crossref_primary_10_1016_j_diabres_2023_111011 crossref_primary_10_1089_dia_2023_0009 crossref_primary_10_1210_clinem_dgae846 crossref_primary_10_3390_pediatric16040100 crossref_primary_10_1111_dom_15868 crossref_primary_10_1007_s00431_023_04833_4 crossref_primary_10_1177_20420188251350210 crossref_primary_10_1089_dia_2022_0287 crossref_primary_10_1089_dia_2023_0081 crossref_primary_10_1089_dia_2025_8814_aln crossref_primary_10_1016_j_clinthera_2025_05_002 crossref_primary_10_1177_19322968251330920 crossref_primary_10_1177_19322968221091842 crossref_primary_10_1089_dia_2022_0206 crossref_primary_10_1002_edm2_469 crossref_primary_10_1016_j_endinu_2023_01_002 crossref_primary_10_1089_dia_2023_0255 crossref_primary_10_1007_s00592_022_01886_z crossref_primary_10_2337_dci24_0007 crossref_primary_10_1016_j_endinu_2022_10_003 crossref_primary_10_1089_dia_2025_18801_rmb crossref_primary_10_1109_ACCESS_2025_3600738 crossref_primary_10_1177_19322968221088608 crossref_primary_10_3389_fendo_2023_1099024 crossref_primary_10_1089_dia_2023_0139 crossref_primary_10_1177_19322968251342239 crossref_primary_10_1016_j_diabres_2025_112035 crossref_primary_10_1089_dia_2023_0379 crossref_primary_10_1089_dia_2023_0412 crossref_primary_10_1007_s00592_024_02397_9 crossref_primary_10_3390_metabo12111137 crossref_primary_10_1007_s00431_024_05551_1 crossref_primary_10_1016_j_diabres_2023_110730 crossref_primary_10_1016_j_eprac_2025_06_004 crossref_primary_10_1089_dtom_2025_0033 crossref_primary_10_1038_s41746_025_01679_y crossref_primary_10_1089_dia_2024_0224 crossref_primary_10_1111_dom_16321 crossref_primary_10_1177_19322968231204376 crossref_primary_10_1089_dia_2023_0529 crossref_primary_10_2337_dc23_1968 crossref_primary_10_2337_dc25_0702 crossref_primary_10_1007_s13300_023_01427_z crossref_primary_10_1089_dia_2024_0586 crossref_primary_10_1016_j_endinu_2024_07_002 crossref_primary_10_1177_19322968241266826 crossref_primary_10_1007_s13300_024_01673_9 crossref_primary_10_1089_dia_2023_0261 crossref_primary_10_1089_dia_2023_0267 crossref_primary_10_1177_19322968241298005 crossref_primary_10_1089_dia_2025_0165 crossref_primary_10_1007_s40138_024_00281_y crossref_primary_10_1089_dia_2022_0542 crossref_primary_10_1089_dia_2022_0148 crossref_primary_10_1136_bmjopen_2023_074984 crossref_primary_10_1007_s40200_024_01397_4 crossref_primary_10_1056_EVIDoa2400185 crossref_primary_10_2196_43535 crossref_primary_10_1089_dtom_2025_0006 crossref_primary_10_1007_s41745_022_00348_3 crossref_primary_10_3389_fendo_2024_1347141 crossref_primary_10_1111_dom_14807 crossref_primary_10_1016_j_diabres_2024_111621 crossref_primary_10_1089_dia_2023_0432 crossref_primary_10_1089_dia_2023_0433 crossref_primary_10_1016_j_mmm_2024_04_002 crossref_primary_10_1016_j_jdiacomp_2024_108795 crossref_primary_10_1089_dia_2022_0491 crossref_primary_10_2337_dsi25_0004 crossref_primary_10_1016_j_eprac_2022_10_001 crossref_primary_10_1111_dom_15217 crossref_primary_10_1089_dia_2022_0375 crossref_primary_10_3389_fendo_2022_1064185 crossref_primary_10_1111_dme_15391 crossref_primary_10_1016_j_endinu_2024_03_002 crossref_primary_10_3390_jcm13051441 crossref_primary_10_1007_s13300_024_01656_w crossref_primary_10_1089_dia_2024_0200 crossref_primary_10_1177_19322968241290259 crossref_primary_10_1213_ANE_0000000000007115 crossref_primary_10_1007_s00592_022_01937_5 crossref_primary_10_1089_dia_2023_2505 crossref_primary_10_1089_dia_2023_0446 crossref_primary_10_1111_pedi_13421 crossref_primary_10_1016_j_endien_2024_03_019 crossref_primary_10_1111_dom_15023 crossref_primary_10_1177_19322968241234948 crossref_primary_10_1089_dia_2025_0068 crossref_primary_10_3389_fendo_2021_802419 crossref_primary_10_3389_fendo_2023_1283181 crossref_primary_10_1016_j_endien_2024_11_010 crossref_primary_10_1080_17434440_2022_2142556 crossref_primary_10_1089_dia_2023_0319 crossref_primary_10_1177_19322968241242386 crossref_primary_10_1177_19322968221106194 crossref_primary_10_1016_j_endien_2022_10_005 crossref_primary_10_1016_j_endien_2023_01_002 crossref_primary_10_1177_19322968221108424 crossref_primary_10_1177_19322968231186976 crossref_primary_10_2337_dc22_0470 crossref_primary_10_1007_s13300_023_01394_5 crossref_primary_10_1089_dia_2023_0293 crossref_primary_10_1007_s10047_025_01510_1 crossref_primary_10_1111_dom_15955 crossref_primary_10_1089_dia_2023_0459 crossref_primary_10_1089_dia_2023_0578 crossref_primary_10_1089_dia_2023_0059 crossref_primary_10_1089_dia_2023_0455 crossref_primary_10_1089_dia_2023_2511 crossref_primary_10_1111_dom_15718 crossref_primary_10_5114_ctd_194183 crossref_primary_10_3390_medicina61091602 crossref_primary_10_1007_s12020_024_03683_w crossref_primary_10_3390_medicina58111671 crossref_primary_10_1038_s41430_024_01422_y |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1089/dia.2021.0203 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-8593 |
| ExternalDocumentID | 34524003 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 29F 34G 39C 4.4 53G 6PF AAWTL ABBKN ABJNI ACGFS ADBBV AENEX AHMBA ALMA_UNASSIGNED_HOLDINGS BNQNF CAG CGR COF CS3 CUY CVF DU5 EBS ECM EIF EJD F5P IAO IER IHR IM4 INH INR ITC MV1 NPM NQHIM O9- PQQKQ RIG RML UE5 7X8 SCNPE |
| ID | FETCH-LOGICAL-c516t-a9d6a62495655068d98d6d1db97ad6b2edb310517c71a95030a9f35943e3d82c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 157 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000968985100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1557-8593 |
| IngestDate | Fri Sep 05 09:15:01 EDT 2025 Thu Jan 02 22:39:46 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Automated insulin delivery Hyperglycemia Diabetes Hypoglycemia Time-in-range Real-world evidence |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c516t-a9d6a62495655068d98d6d1db97ad6b2edb310517c71a95030a9f35943e3d82c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-0273-4732 0000-0003-4337-1795 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8817690 |
| PMID | 34524003 |
| PQID | 2572944326 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2572944326 pubmed_primary_34524003 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Diabetes technology & therapeutics |
| PublicationTitleAlternate | Diabetes Technol Ther |
| PublicationYear | 2022 |
| SSID | ssj0007321 |
| Score | 2.650337 |
| Snippet | The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery. The... Background: The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 113 |
| SubjectTerms | Blood Glucose Blood Glucose Self-Monitoring Diabetes Mellitus, Type 1 - drug therapy Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Infusion Systems Retrospective Studies |
| Title | Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34524003 https://www.proquest.com/docview/2572944326 |
| Volume | 24 |
| WOSCitedRecordID | wos000968985100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELWAIsSFfSmbjMTVahIvsbkghCgcaKkQRT1RxUukXJJCWr6AL-HT-BLGSaqekJC4-GRL1mj85o1nQ-jCOQZmSYckBYQkTGhKEh4YEinGwT4Ypqss35eHuN-Xo5EaNB9uZZNWOcfECqhtYfwfeQdUC84zYBtXkzfip0b56GozQmMZtShQGa_V8WjRLTymdd0V54DEXNGmx2YgVQeED85h5Bt2VvOyfmGXlZXpbv73fltoo-GX-LpWiG205PIdtNZrIui76PUJmCGpUmjwYFE0gIsUAxXEvSzPYPP35xeOZXCH64bml7ibAUvENVv3ex9nU7iWK7EvT8EsjAI89HWbe2jYvX2-uSfNjAVieCimJFFWJMIPoBbgqwhplbTChlarOLFCR85qIIA8jE0cJooDJCQqpVwx6qiVkYn20Upe5O4QYUMdC2gSh044JgOtpRDOgffNjAOWxdrofC65MeiwD0wkuStm5XghuzY6qMU_ntTNNsaUcZ_mSo_-cPoYrUe-OqFKqj5BrRResDtFq-ZjmpXvZ5VywNof9H4ATRLBbg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-World+Performance+of+the+MiniMed%E2%84%A2+780G+System%3A+First+Report+of+Outcomes+from+4120+Users&rft.jtitle=Diabetes+technology+%26+therapeutics&rft.au=Silva%2C+Julien+Da&rft.au=Lepore%2C+Giuseppe&rft.au=Battelino%2C+Tadej&rft.au=Arrieta%2C+Arcelia&rft.date=2022-02-01&rft.eissn=1557-8593&rft.volume=24&rft.issue=2&rft.spage=113&rft_id=info:doi/10.1089%2Fdia.2021.0203&rft_id=info%3Apmid%2F34524003&rft_id=info%3Apmid%2F34524003&rft.externalDocID=34524003 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-8593&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-8593&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-8593&client=summon |